Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarantelli

Showing results (141-150 of 180) with videos related to

Pageof 18
Sort By:
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
European Journal of Medicinal Chemistry|January 12, 2023
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitorMartina De Pascale, Lukas Bissegger, Chiara Tarantelli, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
RSC Medicinal Chemistry|January 22, 2021
Understanding the mechanism of action of pyrrolo[3,2-<i>b</i>]quinoxaline-derivatives as kinase inhibitorsAndrea Unzue, Claudia Jessen-Trefzer, Dimitrios Spiliotopoulos, et al.
Blood Advances|May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsAfua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
American Journal of Respiratory Cell and Molecular Biology|December 15, 2012
Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertensionM Patricia George, Hunter C Champion, Marc Simon, et al.
Biosensors & Bioelectronics: X|January 2, 2023
A DNA biosensors-based microfluidic platform for attomolar real-time detection of unamplified SARS-CoV-2 virusPerrine Robin, Laura Barnabei, Stefano Marocco, et al.
Comparative Medicine|December 14, 2018
Longitudinal Evaluation of Pulmonary Arterial Hypertension in a Rhesus Macaque (<i>Macaca mulatta</i>) Model of HIV InfectionRebecca A Tarantelli, Finja Schweitzer, Marc A Simon, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Pageof 18

Showing results (141-150 of 180) with videos related to

Sort By:
Pageof 18
European Journal of Medicinal Chemistry|August 11, 2019
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell linesAnna Lucia Fallacara, Raffaele Passannanti, Mattia Mori, et al.
Exploration of Targeted Anti-Tumor Therapy|September 1, 2022
The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like typeChiara Tarantelli, Eleonora Cannas, Hillarie Ekeh, et al.
European Journal of Medicinal Chemistry|January 12, 2023
Investigation of morpholine isosters for the development of a potent, selective and metabolically stable mTOR kinase inhibitorMartina De Pascale, Lukas Bissegger, Chiara Tarantelli, et al.
Ejhaem|September 2, 2022
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphomaFilippo Spriano, Giulio Sartori, Chiara Tarantelli, et al.
RSC Medicinal Chemistry|January 22, 2021
Understanding the mechanism of action of pyrrolo[3,2-<i>b</i>]quinoxaline-derivatives as kinase inhibitorsAndrea Unzue, Claudia Jessen-Trefzer, Dimitrios Spiliotopoulos, et al.
Blood Advances|May 17, 2021
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitorsAfua Adjeiwaa Mensah, Filippo Spriano, Giulio Sartori, et al.
American Journal of Respiratory Cell and Molecular Biology|December 15, 2012
Physiologic changes in a nonhuman primate model of HIV-associated pulmonary arterial hypertensionM Patricia George, Hunter C Champion, Marc Simon, et al.
Biosensors & Bioelectronics: X|January 2, 2023
A DNA biosensors-based microfluidic platform for attomolar real-time detection of unamplified SARS-CoV-2 virusPerrine Robin, Laura Barnabei, Stefano Marocco, et al.
Comparative Medicine|December 14, 2018
Longitudinal Evaluation of Pulmonary Arterial Hypertension in a Rhesus Macaque (<i>Macaca mulatta</i>) Model of HIV InfectionRebecca A Tarantelli, Finja Schweitzer, Marc A Simon, et al.
Cancers|June 7, 2019
The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with VenetoclaxChiara Tarantelli, Eugenio Gaudio, Petra Hillmann, et al.
Pageof 18